Patents Assigned to Merck Patents GmbH
  • Patent number: 8999986
    Abstract: Pyrrolo[2,3-d]pyrazin-7-ylpyrimidine compounds are inhibitors of cell proliferation/cell vitality and can be employed for the treatment of tumors.
    Type: Grant
    Filed: November 24, 2010
    Date of Patent: April 7, 2015
    Assignee: Merck Patent GmbH
    Inventors: Margarita Wucherer-Plietker, Christina Esdar
  • Patent number: 8999459
    Abstract: The present invention relates to a liquid-crystal (LC) display of the PSA (polymer sustained alignment) type, and to polymerizable compounds and LC media for use in PSA displays.
    Type: Grant
    Filed: July 30, 2008
    Date of Patent: April 7, 2015
    Assignee: Merck Patent GmbH
    Inventors: Georg Bernatz, Melanie Klasen-Memmer, Matthias Bremer
  • Patent number: 8999348
    Abstract: The present invention relates to the preparation and use of recombinant variants of group 6 allergens of the Poaceae (true grasses), which are characterized by reduced IgE reactivity compared with known wild-type allergens and at the same time substantially retained reactivity with T-lymphocytes.
    Type: Grant
    Filed: December 17, 2010
    Date of Patent: April 7, 2015
    Assignee: Merck Patent GmbH
    Inventors: Martin Wald, Andreas Nandy, Helmut Fiebig, Bernhard Weber, Helga Kahlert, Gerald Reese, Oliver Cromwell
  • Patent number: 8999460
    Abstract: The invention relates to compounds of the formula I, and to a liquid-crystalline medium, preferably having a nematic phase and negative dielectric anisotropy, which comprises one or more compounds of formula I, defined herein, for use in an electro-optical display, particularly in an active-matrix display based on the VA, ECB, PALO, FFS or IPS effect, and to the use of the compounds of the formula I for the stabilization of a liquid-crystalline medium which comprises one or more compounds of the formula II and one or more compounds of the formulae III-1 to III-4, defined herein.
    Type: Grant
    Filed: April 20, 2012
    Date of Patent: April 7, 2015
    Assignee: MERCK PATENT GmbH
    Inventors: Mark Goebel, Rocco Fortte, Detlef Pauluth
  • Patent number: 9000166
    Abstract: The present invention describes novel ionic metal complexes. Compounds of this type can be employed as functional materials in a number of different applications which can be ascribed to the electronics industry in the broadest sense. The compounds according to the invention are described by the formulae (1) and (1a).
    Type: Grant
    Filed: June 9, 2006
    Date of Patent: April 7, 2015
    Assignee: Merck Patent GmbH
    Inventors: Philipp Stoessel, Heinrich Becker, Amir H. Parham, Esther Breuning
  • Publication number: 20150090935
    Abstract: The invention relates to bimesogenic compounds of formula I wherein R11, R12, MG11, MG12, X11, X12 and Sp1 have the meaning given in claim 1, to the use of bimesogenic compounds of formula I in liquid crystal media and particular to flexoelectric liquid crystal devices comprising a liquid crystal medium according to the present invention. Furthermore the invention relates to bimesogenic compounds of formula I inducing a second nematic phase in nematic mixtures that do not show this additional phase without compounds of formula I.
    Type: Application
    Filed: May 7, 2013
    Publication date: April 2, 2015
    Applicant: Merck Patent GmbH
    Inventors: Kevin Adlem, Owain Llyr Parri, Rachel Tuffin, Benjamin Snow, Mariam Namutebi
  • Publication number: 20150092262
    Abstract: This invention relates to particles comprising a core particle and a polymeric shell, electrophoretic fluids comprising such particles, and electrophoretic display devices comprising such fluids.
    Type: Application
    Filed: March 28, 2013
    Publication date: April 2, 2015
    Applicant: Merck Patent GmbH
    Inventors: Nils Greinert, Thomas Bauer, Matthias Koch, Wolfgang Hechler, Thomas Rentschler, Nathan Smith
  • Patent number: 8993103
    Abstract: The present invention relates to a process for the production of three-dimensional patterns in coatings which comprise flake-form effect pigments, to patterned coatings produced thereby and to the use thereof in decoration and security products.
    Type: Grant
    Filed: November 17, 2011
    Date of Patent: March 31, 2015
    Assignee: Merck Patent GmbH
    Inventors: Peter Clauter, Thomas Goetz
  • Patent number: 8993564
    Abstract: Compounds of the formula (I) in which R1, R2 and R3 have the meanings indicated in Claim 1, are inhibitors of PDK1 and cell proliferation/cell vitality and can be employed treatment of tumours.
    Type: Grant
    Filed: May 29, 2012
    Date of Patent: March 31, 2015
    Assignee: Merck Patent GmbH
    Inventors: Timo Heinrich, Margarita Wucherer-Plietker, Hans-Peter Buchstaller
  • Patent number: 8993123
    Abstract: The present invention relates to the compounds of the formula (1) and to organic electroluminescent devices, in particular blue-emitting devices, in which these compounds are used as host material in the emitting layer and/or as electron-transport material.
    Type: Grant
    Filed: February 13, 2009
    Date of Patent: March 31, 2015
    Assignee: Merck Patent GmbH
    Inventors: Arne Buesing, Holger Heil, Philipp Stoessel
  • Patent number: 8993261
    Abstract: The invention relates to antibodies that are capable to bind the extracellular domain of integrin. Another object of the invention concerns the use of said antibodies for detecting integrins in archival formalin fixed paraffin embedded (FFPE) tissue. The invention also relates to methods for preparing monoclonal rabbit antibodies, wherein the immunogen is an insect expression culture-derived recombinant extracellular integrin domain, and another method for screening anti-integrin antibodies that discriminate between closest integrin homologues and that are especially suited for immunohistochemistry in FFPE material.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: March 31, 2015
    Assignee: Merck Patent GmbH
    Inventors: Simon Goodman, Claudia Wilm, Francesc Mitjans
  • Publication number: 20150085472
    Abstract: The present invention relates to Eu-, Sm- or Pr-doped silicate compounds, to a process for the preparation thereof and to the use thereof as conversion phosphors. The present invention also relates to an emission-converting material comprising at least the conversion phosphor according to the invention and to the use thereof in light sources, in particular pc-LEDs (phosphor converted light emitting devices). The present invention furthermore relates to light sources, in particular pc-LEDs, and lighting units which contain a primary light source and the emission-converting material according to the invention.
    Type: Application
    Filed: March 22, 2013
    Publication date: March 26, 2015
    Applicant: Merck Patent GmbH
    Inventors: Holger Winkler, Thomas Juestel, Arturas Katelnikovas, Florian Baur
  • Patent number: 8987301
    Abstract: Novel hetarylaminoquinoline derivatives of formula (I) wherein X, Z, Het, R1, R2, R3 and R4 have the meaning according to claim 1, are inhibitors of ATP consuming proteins, and can be employed, inter alia, for the treatment of tumors.
    Type: Grant
    Filed: October 12, 2010
    Date of Patent: March 24, 2015
    Assignee: Merck Patent GmbH
    Inventors: Alfred Jonczyk, Christiane Amendt, Frank Zenke
  • Patent number: 8987687
    Abstract: The invention relates to compounds of the general formula I (Ba1-a-bSraEub)2+x(Lu1-c-dYcGdd)2?x(PO4)2+x(SiO4)1?x??(I) where b stands for a value from the range 0<b?0.2 a, c, d stand, independently of one another, for a value from the range from 0 to 1 x stands for a value from the range from 0 to 0.8, and to a process for the preparation of these phosphors and to the use thereof as conversion phosphors or in lamps.
    Type: Grant
    Filed: August 16, 2011
    Date of Patent: March 24, 2015
    Assignee: Merck Patent GmbH
    Inventors: Holger Winkler, Thomas Juestel, Arturas Kastelnikovas, Olga Darcanova
  • Patent number: 8986852
    Abstract: The present invention relates to the compounds of the formula (1) and to organic electroluminescent devices, in particular blue-emitting devices, in which these compounds are used as host material or dopant in the emitting layer and/or as hole-transport material and/or as electron-transport material.
    Type: Grant
    Filed: April 29, 2008
    Date of Patent: March 24, 2015
    Assignee: Merck Patent GmbH
    Inventors: Philipp Stoessel, Arne Buesing, Holger Heil
  • Publication number: 20150076418
    Abstract: The invention relates to novel conjugated polymers comprising in their backbone one or more divalent donor units, like for example benzo[1,2-b:4,5-b?]dithiophene-2,6-diyl (BDT), that are linked on both sides to an acceptor unit, to methods of preparing the polymers and educts or intermediates used in such preparation, to polymer blends, mixtures and formulations containing the polymers, to the use of the polymers, polymer blends, mixtures and formulations as semiconductors organic electronic (OE) devices, especially in organic photovoltaic (OPV) devices and organic photodetectors (OPD), and to OE, OPV and OPD devices comprising these polymers, polymer blends, mixtures or formulations.
    Type: Application
    Filed: February 15, 2013
    Publication date: March 19, 2015
    Applicant: MERCK PATENT GMBH
    Inventors: Nicolas Blouin, Amy Phillips, Lana Nanson, Steven Tierney, Toby Cull, Priti Tiwana, Stephane Berney, Miguel Carrasco-Orozco, Frank Egon Meyer
  • Publication number: 20150079120
    Abstract: The present invention relates to the preparation and use of recombinant variants of group 6 allergens of the Poaceae (true grasses), which are characterised by reduced IgE reactivity compared with known wild-type allergens and at the same time substantially retained reactivity with T-lymphocytes.
    Type: Application
    Filed: November 21, 2014
    Publication date: March 19, 2015
    Applicant: Merck Patent GmbH
    Inventors: Helmut FIEBIG, Andreas NANDY, Roland SUCK, Oliver CROMWELL, Arnd PETERSEN, Wolf-Meinhard BECKER
  • Patent number: 8980324
    Abstract: The invention relates to ultrasmall, monodisperse nanoparticles comprising silicon dioxide to the surface of which at least one antigen is attached. The nanoparticles can be used for the immunoprophylaxis or immunotherapy of cancer. The invention also relates to a method for the targeting of antigens at antigen-presenting cells and for the activation of the immune system, where the efficiency of targeting and/or immunoactivation are set via the particle characteristics. The invention also relates to a method for the active and passive immunization of a mammal.
    Type: Grant
    Filed: July 13, 2009
    Date of Patent: March 17, 2015
    Assignee: Merck Patent GmbH
    Inventors: Markus Weigandt, Andrea Hanefeld, Armin Kuebelbeck, Gregor Larbig
  • Patent number: 8980977
    Abstract: The present invention relates to pigment granules which are distinguished by the fact that they are based on a support material, where the support material is coated with one or more flake-form effect pigments by means of an adhesion promoter. The pigment granules according to the invention are preferably used for the pigmentation of application media, in particular paints, plasters, lacquers, powder coatings and plastics, and in particular as scatter and effect granules, for example for the decoration of wallcoverings.
    Type: Grant
    Filed: August 26, 2011
    Date of Patent: March 17, 2015
    Assignee: Merck Patent GmbH
    Inventors: Thomas Rathschlag, Carsten Griessmann
  • Patent number: 8981101
    Abstract: Compounds of the formula (I) in which R, R1, R2 and R3 have the meanings indicated in claim 1, are inhibitors of PDK1 and cell proliferation/cell vitality and can be employed for the treatment of tumors.
    Type: Grant
    Filed: January 9, 2012
    Date of Patent: March 17, 2015
    Assignee: Merck Patent GmbH
    Inventors: Dieter Dorsch, Christian Sirrenberg, Thomas J. J. Mueller, Eugen Merkul, Gnuni Amatunu Karapetyan